Low-dose multicomponent medication modulates humoral and cellular immune response in an ex-vivo study on children subjected to adenoid surgery

Sara Carlotta Tagliacarne, Chiara Valsecchi, Marco Benazzo, Michele Nichelatti, Alessia Marseglia, Giorgio Ciprandi, Sergio Bernasconi

Research output: Contribution to journalArticle

Abstract

Respiratory infections, mainly in children, are a demanding challenge for physicians. Commonly, a relative immune-defect sustains their recurrence. At present, there is no standardized treatment for their prevention acting on the immune system. Citomix is a low-dose multicomponent medication largely used in this issue. The current study evaluated its ex vivo effect on adenoidal mononuclear cells recovered from children operated for adenoid hypertrophy. B cell phenotype, and IFN-γ, IL-6, IL-10, IgG, IgA, IgM in culture supernatants were evaluated. Citomix was able to significantly increase the expression of B memory cells, IFN-γ, IL-6, IgA and IgM, and significantly decrease IL-10 and IgG. The current outcomes could be consistent with a strategy deputed to improve the early immune response to pathogens. In conclusion, the present ex vivo study suggests that Citomix might be a promising medication in preventing and early treating respiratory infections.

Original languageEnglish
Pages (from-to)95-101
Number of pages7
JournalImmunology Letters
Volume203
DOIs
Publication statusPublished - Nov 1 2018

Fingerprint

Adenoids
Humoral Immunity
Cellular Immunity
Respiratory Tract Infections
Interleukin-10
Immunoglobulin A
Immunoglobulin M
Interleukin-6
Immunoglobulin G
Hypertrophy
Immune System
B-Lymphocytes
Physicians
Phenotype
Recurrence
Therapeutics

Keywords

  • Adenoidal cells
  • B memory cells
  • Children
  • IFN-γ
  • IgA
  • IgG
  • IgM
  • IL-10
  • IL-6
  • Low-dose multicomponent medication
  • Respiratory infections
  • SKA (sequential kinetic activation)

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Low-dose multicomponent medication modulates humoral and cellular immune response in an ex-vivo study on children subjected to adenoid surgery. / Tagliacarne, Sara Carlotta; Valsecchi, Chiara; Benazzo, Marco; Nichelatti, Michele; Marseglia, Alessia; Ciprandi, Giorgio; Bernasconi, Sergio.

In: Immunology Letters, Vol. 203, 01.11.2018, p. 95-101.

Research output: Contribution to journalArticle

Tagliacarne, Sara Carlotta ; Valsecchi, Chiara ; Benazzo, Marco ; Nichelatti, Michele ; Marseglia, Alessia ; Ciprandi, Giorgio ; Bernasconi, Sergio. / Low-dose multicomponent medication modulates humoral and cellular immune response in an ex-vivo study on children subjected to adenoid surgery. In: Immunology Letters. 2018 ; Vol. 203. pp. 95-101.
@article{d850c91077d847ad9506e3c89f2ff25a,
title = "Low-dose multicomponent medication modulates humoral and cellular immune response in an ex-vivo study on children subjected to adenoid surgery",
abstract = "Respiratory infections, mainly in children, are a demanding challenge for physicians. Commonly, a relative immune-defect sustains their recurrence. At present, there is no standardized treatment for their prevention acting on the immune system. Citomix is a low-dose multicomponent medication largely used in this issue. The current study evaluated its ex vivo effect on adenoidal mononuclear cells recovered from children operated for adenoid hypertrophy. B cell phenotype, and IFN-γ, IL-6, IL-10, IgG, IgA, IgM in culture supernatants were evaluated. Citomix was able to significantly increase the expression of B memory cells, IFN-γ, IL-6, IgA and IgM, and significantly decrease IL-10 and IgG. The current outcomes could be consistent with a strategy deputed to improve the early immune response to pathogens. In conclusion, the present ex vivo study suggests that Citomix might be a promising medication in preventing and early treating respiratory infections.",
keywords = "Adenoidal cells, B memory cells, Children, IFN-γ, IgA, IgG, IgM, IL-10, IL-6, Low-dose multicomponent medication, Respiratory infections, SKA (sequential kinetic activation)",
author = "Tagliacarne, {Sara Carlotta} and Chiara Valsecchi and Marco Benazzo and Michele Nichelatti and Alessia Marseglia and Giorgio Ciprandi and Sergio Bernasconi",
year = "2018",
month = "11",
day = "1",
doi = "10.1016/j.imlet.2018.09.014",
language = "English",
volume = "203",
pages = "95--101",
journal = "Immunology Letters",
issn = "0165-2478",
publisher = "Elsevier",

}

TY - JOUR

T1 - Low-dose multicomponent medication modulates humoral and cellular immune response in an ex-vivo study on children subjected to adenoid surgery

AU - Tagliacarne, Sara Carlotta

AU - Valsecchi, Chiara

AU - Benazzo, Marco

AU - Nichelatti, Michele

AU - Marseglia, Alessia

AU - Ciprandi, Giorgio

AU - Bernasconi, Sergio

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Respiratory infections, mainly in children, are a demanding challenge for physicians. Commonly, a relative immune-defect sustains their recurrence. At present, there is no standardized treatment for their prevention acting on the immune system. Citomix is a low-dose multicomponent medication largely used in this issue. The current study evaluated its ex vivo effect on adenoidal mononuclear cells recovered from children operated for adenoid hypertrophy. B cell phenotype, and IFN-γ, IL-6, IL-10, IgG, IgA, IgM in culture supernatants were evaluated. Citomix was able to significantly increase the expression of B memory cells, IFN-γ, IL-6, IgA and IgM, and significantly decrease IL-10 and IgG. The current outcomes could be consistent with a strategy deputed to improve the early immune response to pathogens. In conclusion, the present ex vivo study suggests that Citomix might be a promising medication in preventing and early treating respiratory infections.

AB - Respiratory infections, mainly in children, are a demanding challenge for physicians. Commonly, a relative immune-defect sustains their recurrence. At present, there is no standardized treatment for their prevention acting on the immune system. Citomix is a low-dose multicomponent medication largely used in this issue. The current study evaluated its ex vivo effect on adenoidal mononuclear cells recovered from children operated for adenoid hypertrophy. B cell phenotype, and IFN-γ, IL-6, IL-10, IgG, IgA, IgM in culture supernatants were evaluated. Citomix was able to significantly increase the expression of B memory cells, IFN-γ, IL-6, IgA and IgM, and significantly decrease IL-10 and IgG. The current outcomes could be consistent with a strategy deputed to improve the early immune response to pathogens. In conclusion, the present ex vivo study suggests that Citomix might be a promising medication in preventing and early treating respiratory infections.

KW - Adenoidal cells

KW - B memory cells

KW - Children

KW - IFN-γ

KW - IgA

KW - IgG

KW - IgM

KW - IL-10

KW - IL-6

KW - Low-dose multicomponent medication

KW - Respiratory infections

KW - SKA (sequential kinetic activation)

UR - http://www.scopus.com/inward/record.url?scp=85054422305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054422305&partnerID=8YFLogxK

U2 - 10.1016/j.imlet.2018.09.014

DO - 10.1016/j.imlet.2018.09.014

M3 - Article

AN - SCOPUS:85054422305

VL - 203

SP - 95

EP - 101

JO - Immunology Letters

JF - Immunology Letters

SN - 0165-2478

ER -